• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94)
 

Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94)

Options
  • Details
Publisher DOI
10.1016/j.radonc.2012.05.004
PubMed ID
22726581
Description
This secondary analysis was performed to identify predictive factors for severe late radiotherapy (RT)-related toxicity after treatment with hyperfractionated RT +/- concomitant cisplatin in locally advanced head and neck cancer.
Date of Publication
2012
Publication Type
Article
Language(s)
en
Contributor(s)
Ghadjar, Pirus
Universitätsklinik für Radio-Onkologie
Simcock, Mathew
Zimmermann, Frank
Betz, Michael
Bodis, Stephan
Bernier, Jacques
Studer, Gabriela
Aebersold, Daniel Matthiasorcid-logo
Universitätsklinik für Radio-Onkologie
Swiss Group for Clinical Cancer Research (SAKK)
Additional Credits
Universitätsklinik für Radio-Onkologie
Series
Radiotherapy and oncology
Publisher
Elsevier
ISSN
0167-8140
Access(Rights)
metadata.only
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo